Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease

Article type: Research Article

Authors: Domenighetti, Cloé^a | Sugier, Pierre-Emmanuel^a | Sreelatha, Ashwin Ashok Kumar^b | Schulte, Claudia^{c; d} | Grover, Sandeep^b | Mohamed, Océane^a | Portugal, Berta^a | May, Patrick^e | Bobbili, Dheeraj R.^{e; f} | Radivojkov-Blagojevic, Milena^g | Lichtner, Peter^g | Singleton, Andrew B.^{h; i} | Hernandez, Dena G.^h | Edsall, Connor^h | Mellick, George D.^j | Zimprich, Alexander^k | Pirker, Walter^l | Rogaeva, Ekaterina^m | Lang, Anthony E.^{n; o; p} | Koks, Sulev^{q; r} | Taba, Pille^{s; t} | Lesage, Suzanne^u | Brice, Alexis^u | Corvol, Jean-Christophe^{u; v} | Chartier-Harlin, Marie-Christine^w | Mutez, Eugénie^w | Brockmann, Kathrin^{c; d} | Deutschländer, Angela B.^{x; y; z} | Hadjigeorgiou, Georges M.^{aa; ab} | Dardiotis, Efthimos^aa | Stefanis, Leonidas^{ac; ad} | Simitsi, Athina Maria^ac | Valente, Enza Maria^{ae; af} | Petrucci, Simona^{ag; ah} | Duga, Stefano^{ai; aj} | Straniero, Letizia^ai | Zecchinelli, Anna^ak | Pezzoli, Gianni^ak | Brighina, Laura^{al; am} | Ferrarese, Carlo^{al; am} | Annesi, Grazia^an | Quattrone, Andrea^ao | Gagliardi, Monica^ap | Matsuo, Hirotaka^aq | Kawamura, Yusuke^aq | Hattori, Nobutaka^ar | Nishioka, Kenya^ar | Chung, Sun Ju^as | Kim, Yun Joong^at | Kolber, Pierre^au | van de Warrenburg, Bart PC^av | Bloem, Bastiaan R.^av | Aasly, Jan^aw | Toft, Mathias^ax | Pihlstrøm, Lasse^ax | Guedes, Leonor Correia^{ay; az} | Ferreira, Joaquim J.^{ay; ba} | Bardien, Soraya^bb | Carr, Jonathan^bc | Tolosa, Eduardo^{bd; be} | Ezquerra, Mario^bf | Pastor, Pau^{bg; bh} | Diez-Fairen, Monica^{bg; bh} | Wirdefeldt, Karin^{bi; bj} | Pedersen, Nancy L.^bj | Ran, Caroline^bk | Belin, Andrea C.^bk | Puschmann, Andreas^bl | Hellberg, Clara^bl | Clarke, Carl E.^bm | Morrison, Karen E.^bn | Tan, Manuela^bo | Krainc, Dimitri^bp | Burbulla, Lena F.^bp | Farrer, Matt J.^bq | Krüger, Rejko^{e; au; br; bs} | Gasser, Thomas^{c; d} | Sharma, Manu^{b; c} | Elbaz, Alexis^{a; *} | on behalf of the Comprehensive Unbiaised Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease (Courage-PD) consortium

Affiliations: [a] Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health", CESP, Villejuif, France | [b] Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany | [c] Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany | [d] German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany | [e] Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg | [f] MeGeno S.A, Esch-sur-Alzette, Luxembourg | [g] Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany | [h] Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA | [i] Center For Alzheimer’s and Related Dementias, NIA, NIH, Bethesda, MD, USA | [j] Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia | [k] Department of Neurology, Medical University of Vienna, Austria | [l] Department of Neurology, Wilhelminenspital, Austria | [m] Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada | [n] Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada | [o] Division of Neurology, University of Toronto, Toronto, Ontario, Canada | [p] Krembil Brain Institute, Toronto, Ontario, Canada | [q] Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia | [r] Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia | [s] Department of Neurology and Neurosurgery, University of Tartu, Estonia | [t] Neurology Clinic, Tartu University Hospital, Tartu, Estonia | [u] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France | [v] Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Paris, France | [w] Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France | [x] Department of Neurology, Ludwig Maximilians University of Munich, Germany | [y] Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany | [z] Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, FL, USA | [aa] Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece | [ab] Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus | [ac] 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece | [ad] Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece | [ae] Department of Molecular Medicine, University of Pavia, Pavia, Italy | [af] Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy | [ag] UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy | [ah] Department of Clinical and Molecular Medicine, University of Rome, Rome, Italy | [ai] Department of Biomedical Sciences - Humanitas University, Milan, Italy | [aj] Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy | [ak] Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy | [al] Department of Neurology, San Gerardo Hospital, Monza, Italy | [am] Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milano, Italy | [an] Institute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy | [ao] Institute of Neurology, Magna Graecia University, Catanzaro, Italy | [ap] Institute of Molecular Bioimaging and Physiology National Research Council, Catanzaro, Italy | [aq] Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan | [ar] Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan | [as] Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea | [at] Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea | [au] Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg | [av] Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands | [aw] Department of Neurology, St Olav’s Hospital and Norwegian University of Science and Technology, Trondheim, Norway | [ax] Department of Neurology, Oslo University Hospital, Oslo, Norway | [ay] Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal | [az] Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN), Lisbon, Portugal | [ba] Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal | [bb] Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa | [bc] Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa | [bd] Parkinson’s disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain | [be] Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona, Spain | [bf] Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia | [bg] Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain | [bh] Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain | [bi] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden | [bj] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden | [bk] Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden | [bl] Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden | [bm] University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, UK | [bn] Faculty of Medicine, Health and Life Sciences, Queens University, Belfast, UK | [bo] Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK | [bp] Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA | [bq] Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA | [br] Parkinson’s Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg | [bs] Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg

Correspondence: [*] Correspondence to: Alexis Elbaz, INSERM U1018 CESP, Hôpital Paul Brousse, Bâtiment 15/16, 16 avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France. Tel.: +33 1 45595370; E-mail: alexis.elbaz@inserm.fr.

Abstract: Background:Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson’s disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation. Objective:To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases. Methods:We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017). Results:We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60–0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking. Conclusion:Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.

Keywords: Smoking, alcohol, coffee, Parkinson’s disease, Mendelian randomisation

DOI: 10.3233/JPD-212851

Journal: Journal of Parkinson's Disease, vol. 12, no. 1, pp. 267-282, 2022